Barinthus Biotherapeutics (NASDAQ:BRNS) vs. Entera Bio (NASDAQ:ENTX) Head to Head Survey

Entera Bio (NASDAQ:ENTX) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 10.4% of Entera Bio shares are held by company insiders. Comparatively, 10.7% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Entera Bio and Barinthus Biotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$180,000.00	349.05	-$9.54 million	($0.25)	-5.48
Barinthus Biotherapeutics	$14.97 million	1.99	-$61.07 million	($1.88)	-0.39

Entera Bio has higher earnings, but lower revenue than Barinthus Biotherapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Entera Bio and Barinthus Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-67.56%	-59.50%
Barinthus Biotherapeutics	N/A	-70.13%	-56.09%

Volatility and Risk

Entera Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.66, meaning that its share price is 166% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Entera Bio and Barinthus Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1	0	0	1	2.50
Barinthus Biotherapeutics	1	0	2	0	2.33

Entera Bio currently has a consensus price target of $10.00, suggesting a potential upside of 629.93%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 447.95%. Given Entera Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Barinthus Biotherapeutics.

Summary

Entera Bio beats Barinthus Biotherapeutics on 8 of the 14 factors compared between the two stocks.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.